Dry eye & MGD
Conditions
Interventions
A1 Medicine Treatment Group:0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
A2 Conbined Treatment Group:0.3% sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, with meibomian gland massage, 28 days
B1 Contral Group:placebo
B2 Experimental Group:0.3% sodium hyaluronate ophthalmic solution, 1 year
Sponsors
Shenzhen Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, diagnosed with glaucoma, including primary open-angle glaucoma or primary angle closure glaucoma, require treatment with anti-glaucoma eye drops; 2. group A: Patients using glaucoma eye drops longer than 6 months, and in accordance with the diagnostic criteria of dry eye: (1) Subjective symptoms (required): dryness, foreign body sensation, fatigue and discomfort; (2) The instability of tear film (required): tear break up time(TBUT); (3) Lacrimal secretion: Schirmer I test; (4) The ocular surface damage (strengthen diagnosis): fluorescein staining(FL); in the mentioned in (1)+(2)(TBUT=5s) or (1)+(2)(TBUT=10s)+(3)(<10mm)/(4)(FL+); 3. The choice of study eyes: Choose the eye of the patient with low basical intraocular pressure, and if the basal intraocular pressure is the same, choose the right eye for the study; 4. Voluntary participation in this clinical study, and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. With metabolic diseases, autoimmune diseases, connective tissue diseases, such as diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome ect; 2. Combined with cerebrovascular, liver, kidney, hematopoietic serious system desease, atumor diseases and psychosis; 3. Using any artificial tears and except any clinical trials of dry eyes within two weeks; 4. With drug therapy, embolization and surgical treatment of dry eyes; 5. With other eye diseases, such as eyelid defects, hypophasis, pterygium, chronic dacryocystitis, trichiasis, corneal lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TBUT;Schirmer Test;Corneal staining scores;Ocular Surface Disease Index(OSDI); | — |
Secondary
| Measure | Time frame |
|---|---|
| conjunctival congestion;eyelid edge change;the nature of meibomain gland section; | — |
Countries
China
Contacts
Public ContactYingli Li
Shenzhen Hospital of Southern Medical University
Outcome results
None listed